New ICH guideline revisions are imminent. Sue Batchelor of Cmed shares her thoughts on how sponsors and CROs can prepare themselves.

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

A whistle-stop tour of the mechanisms, benefits, manufacturing challenges, and clinical potential of CAR T cells, TCR T cells, TILs, and NK cells.

To optimize drug development, the opinions of all stakeholders – including patients – must be heard.

Joe Sinclair gives his view on how to be successful with oncolytic virotherapy.

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

Watch our video interview with We interview Joe Healey, CEO and Co-Founder of NanoSyrinx.

It's time for pharma fight back against fake news, says Ahmed Samy of eureka!digital.

We interview Tamas Masztis, Senior Director, Cell Therapy Supply Chain for Europe, Kite, a Gilead Company.

We interview Sharon Brownlow from the Cell & Gene Therapy Catapult about her career and the top trends in cell therapy.